Article Text

Download PDFPDF
Refractory adult onset Still’s disease and hypersensitivity to non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors: are biological agents the solution?
  1. E H J G Aarntzen,
  2. P L C M van Riel,
  3. P Barrera
  1. Department of Rheumatology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
  1. Correspondence to:
    Dr P Barrera
    p.barrerareuma.umcn.nl

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Adult onset Still’s disease (AOSD) is an autoimmune disorder characterised by periodic high fever, arthritis, and typical evanescent rashes. Non-steroidal anti-inflammatory drugs (NSAIDs) are the preferred treatment. In severe cases several disease modifying antirheumatic drugs, thalidomide, and intravenous immunoglobulin have been used. More recently, successful treatment with tumour necrosis factor α (TNFα) blocking agents1,2 and interleukin (IL) 1 neutralisation3 has also been reported.

Hypersensitivity to NSAIDs, often characterised by urticaria, angio-oedema, and asthma, has been well documented, and several studies indicate that anaphylactic reactions are related to the inhibition of cyclo-oxygenase-1 (COX-1) enzyme4–6 and that selective COX-2 inhibitors can be safe in these patients. Here we report a case of AOSD complicated by coexisting hypersensitivity …

View Full Text

Footnotes

  • Competing interests: none

  • Published Online First 13 July 2005